Breast Cancer

Equivalence Trial of Neoadjuvant Trastuzumab Biosimilar CT-P6 vs Trastuzumab in HER2-Positive Breast Cancer

A phase III equivalence trial has shown comparable pathologic complete response rates with the proposed trastuzumab biosimilar CT-P6 vs reference trastuzumab in neoadjuvant...

Lung Cancer

Adjuvant Gefitinib Delays Recurrence in EGFR-Positive NSCLC

Adjuvant therapy with gefitinib, an epidermal growth factor receptor (EGFR)-targeted agent, was more successful at preventing recurrence than standard-of-care chemotherapy, in a phase III...

Lymphoma

ICML 2017: 3-Year Follow-up Showed Fourfold Progression-Free Survival Benefit With Ibrutinib vs Temsirolimus at First Relapse in Mantle Cell Lymphoma

Three-year follow-up data from the phase III RAY study in patients with relapsed or refractory mantle cell lymphoma were presented at the 14th International Conference on Malignant...


Advertisement

More Top Stories

Head and Neck Cancer

David G. Pfister, MD, on HPV and Head and Neck Cancer

Help Your Patients Catch Up on the Latest Research From the 2017 ASCO Annual Meeting

On the Cancer.Net blog (www.cancer.net/blog), your patients can learn about the research highlighted at the 2017 ASCO Annual Meeting, including what it means for their care and treatment. They can also follow the blog for additional updates from the Meeting, including podcasts with ASCO experts...

Advertisement

Phase III CASCADE Trial of Front-Line Vadastuximab Talirine in AML Discontinued

Seattle Genetics has discontinued its phase III CASCADE clinical trial of front-line vadastuximab talirine (SGN-CD33A) in older acute myeloid leukemia (AML) patients. The phase III CASCADE clinical trial is a randomized, double-blind, placebo-controlled study evaluating vadastuximab talirine...

Survivorship

Todd M. Gibson, PhD, on Childhood Cancer Survivors: Chronic Disease Trends

Leukemia

Venetoclax Achieves Durable and Deep Remissions in CLL

Preliminary study results suggest that venetoclax (Venclexta) plus rituximab (Rituxan) is a highly active combination in relapsed/refractory chronic lymphocytic leukemia (CLL), achieving durable responses and minimal residual disease negativity in previously treated patients. “The results of...

Breast Cancer
Symptom Management

Lymphedema Risk: It’s Not Just About the Surgery

In a study from the Mayo Clinic, Rochester, Minnesota, the risk of lymphedema in a population-based breast cancer cohort was related to multimodality therapy and not axillary surgery alone, investigators reported at the American Society of Breast Surgeons (ASBrS) Annual Meeting.1 “Most patients...

NCCN Guidelines® Compliance for Chest CT May Reduce False Positives and Decrease Health-Care Spending in Breast Cancer

According to Surveillance, Epidemiology, and End Results (SEER) data, more than 260,000 women were diagnosed with breast cancer in the United States in 2016, most of whom were diagnosed with early-stage (stage I or II) disease. For this demographic, the National Comprehensive Cancer Network®...

Hematologic Malignancies

Ruben A. Mesa, MD, on Myeloproliferative Neoplasms and Myelofibrosis: New Treatment Guidelines

Lung Cancer

FDA Broadens Ceritinib Indication

On May 26, 2017, the U.S. Food and Drug Administration (FDA) granted regular approval to ceritinib (Zykadia), a kinase inhibitor for patients with metastatic non–small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)-positive as detected by an FDA-approved test. In April...

Advertisement

Canadian Cancer Society Report: Nearly 1 in 2 Canadians Expected to Be Diagnosed With Cancer in Their Lifetime

Nearly 1 in 2 Canadians is expected to be diagnosed with cancer in their lifetime, according to a new report—Canadian Cancer Statistics 2017—released by the Canadian Cancer Society (CCS) in partnership with the Public Health Agency of Canada and Statistics Canada. For males, the...


click me